| 1.5 0.15 (11.11%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.35 | 1-year : | 6.19 |
| Resists | First : | 3.72 | Second : | 5.3 |
| Pivot price | 2.01  |
|||
| Supports | First : | 1.19 | Second : | 0.99 |
| MAs | MA(5) : | 1.47 |
MA(20) : | 2.1 |
| MA(100) : | 8.72 |
MA(250) : | 16.25 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 10.8 |
D(3) : | 13.4 |
| RSI | RSI(14): 33.8 |
|||
| 52-week | High : | 46.45 | Low : | 1.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AKAN ] has closed above bottom band by 26.6%. Bollinger Bands are 56.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.7 - 1.71 | 1.71 - 1.72 |
| Low: | 1.39 - 1.4 | 1.4 - 1.41 |
| Close: | 1.48 - 1.5 | 1.5 - 1.51 |
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Fri, 23 Jan 2026
Akanda Raises $7 Million Through Convertible Note Private Placement - TipRanks
Fri, 23 Jan 2026
Akanda secures $7M, channels funds to marketing and debt - Stock Titan
Tue, 20 Jan 2026
Major Investor Makes Bold Moves in Akanda Corp Stock Shake-Up - TipRanks
Tue, 20 Jan 2026
Insider Sell: Financial Hrt Sells Shares of Akanda Corp (AKAN) - GuruFocus
Tue, 20 Jan 2026
Strategic Expansion Boosts Akanda Corp.’s Stock - StocksToTrade
Tue, 20 Jan 2026
Akanda Corp. Raises $7 Million via 12-Month Convertible Note Financing - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 25 (K) |
| EPS | 154.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.67 |
| Profit Margin | -266.4 % |
| Operating Margin | -443.9 % |
| Return on Assets (ttm) | -28.7 % |
| Return on Equity (ttm) | -60.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.43 |
| Sales Per Share | 5.74 |
| EBITDA (p.s.) | -25.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.06 |
| Price to Sales | 0.26 |
| Price to Cash Flow | -0.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|